Delhi, June 2: Gilead Sciences Inc’s antiviral drug Remdesivir has been approved by the Central Drugs Standard Control Organisation (CDSCO) for emergency use in treating hospitalised severe COVID-19 patients in
India, as a five day course. Remdesivir is the first drug to show improvement in Covid-19 patients in formal clinical trials.
The drug, manufactured by the American biopharma giant Gilead Sciences, will be imported by Mumbai-based Klinera Global Services from the manufacturing sites of Gilead, Jubilant HollisterStier and Patheon Manufacturing Services in the United States.